Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
– TransCon hGH is a once-weekly prodrug of somatropin designed to reduce the treatment burden for patients with growth hormone deficiency. – Final European Commission decision on TransCon hGH MAA...
-
– SKYTROFA® (lonapegsomatropin-tcgd) approved by the FDA in the U.S. as a once-weekly treatment for pediatric growth hormone deficiency (GHD); commercially launched in October 2021. – Completed...
-
- In non-clinical models, a single dose of TransCon™ TLR7/8 Agonist activated critical innate and adaptive immune mechanisms, providing sustained modulation of tumor microenvironments with low...
-
COPENHAGEN, Denmark, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today provided an update on the Company’s previously announced $25 million American Depositary Shares (ADS)...
-
COPENHAGEN, Denmark, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), today announced that the Company will hold a conference call and live webcast on Wednesday, November 10,...
-
COPENHAGEN, Denmark, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), today announced the U.S. commercial launch of SKYTROFA (lonapegsomatropin-tcgd), its once-weekly treatment...
-
– Late-breaking oral presentation will feature a comprehensive review of 58-week results from the company’s Phase 2 PaTH Forward Trial – COPENHAGEN, Denmark, Sept. 30, 2021 (GLOBE NEWSWIRE)...
-
COPENHAGEN, Denmark, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to potentially create new...
-
– Data from subjects with available dual energy x-ray absorptiometry (DXA) scans demonstrated stabilization of BMD, in alignment with observed bone turnover markers previously reported – COPENHAGEN,...
-
COPENHAGEN, Denmark, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to potentially create new...